PTSD deficiency is a dubious disease that belongs to the field of genetic metabolism, clinical performance is complex and often involves multiple systems. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of PTSD requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PTSD deficiency requires the development of multiple treatment programs, typically including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic diseases have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting timely to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the lack of PTPS. The platform serves a team of domestic and foreign experts in the field of genetic metabolism linked to the China International Medical Service System, providing patients with the following services: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.